654 related articles for article (PubMed ID: 25346165)
21. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
[TBL] [Abstract][Full Text] [Related]
22. Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis.
Lehman NL; Usubalieva A; Lin T; Allen SJ; Tran QT; Mobley BC; McLendon RE; Schniederjan MJ; Georgescu MM; Couce M; Dulai MS; Raisanen JM; Al Abbadi M; Palmer CA; Hattab EM; Orr BA
Acta Neuropathol Commun; 2019 Mar; 7(1):42. PubMed ID: 30876455
[TBL] [Abstract][Full Text] [Related]
23. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
[TBL] [Abstract][Full Text] [Related]
24. Epithelioid GBMs show a high percentage of BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Birks DK; Foreman NK
Am J Surg Pathol; 2013 May; 37(5):685-98. PubMed ID: 23552385
[TBL] [Abstract][Full Text] [Related]
25. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
[TBL] [Abstract][Full Text] [Related]
26. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600E mutation in epilepsy-associated glioneuronal tumors: Prevalence and correlation with clinical features in a Chinese population.
Zhang YX; Shen CH; Guo Y; Zheng Y; Zhu JM; Ding Y; Tang YL; Wang S; Ding MP
Seizure; 2017 Feb; 45():102-106. PubMed ID: 27984807
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors.
Prabowo AS; Iyer AM; Veersema TJ; Anink JJ; Schouten-van Meeteren AY; Spliet WG; van Rijen PC; Ferrier CH; Capper D; Thom M; Aronica E
Brain Pathol; 2014 Jan; 24(1):52-66. PubMed ID: 23941441
[TBL] [Abstract][Full Text] [Related]
29. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma.
Koelsche C; Sahm F; Paulus W; Mittelbronn M; Giangaspero F; Antonelli M; Meyer J; Lasitschka F; von Deimling A; Reuss D
Neuropathol Appl Neurobiol; 2014 Apr; 40(3):337-44. PubMed ID: 23822828
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT
Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754
[TBL] [Abstract][Full Text] [Related]
31. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J
Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727
[TBL] [Abstract][Full Text] [Related]
32. Multiplex ligation-dependent probe amplification analysis is useful for detecting a copy number gain of the FGFR1 tyrosine kinase domain in dysembryoplastic neuroepithelial tumors.
Matsumura N; Nobusawa S; Ito J; Kakita A; Suzuki H; Fujii Y; Fukuda M; Iwasaki M; Nakasato N; Tominaga T; Natsume A; Mikami Y; Shinojima N; Yamazaki T; Nakazato Y; Hirato J; Yokoo H
J Neurooncol; 2019 May; 143(1):27-33. PubMed ID: 30825062
[TBL] [Abstract][Full Text] [Related]
33. Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.
Aisner DL; Newell KL; Pollack AG; Kleinschmidt-Demasters BK; Steinberg GK; Smyth LT; Vogel H
Clin Neuropathol; 2014; 33(2):112-21. PubMed ID: 24321241
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
[TBL] [Abstract][Full Text] [Related]
35. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
36. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
[TBL] [Abstract][Full Text] [Related]
39. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
40. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]